在美银上调目标价、关键癌症疫苗试验结果即将公布之际,莫德纳收复部分失地

路透中文
Oct 19
BUZZ-在美银上调目标价、关键癌症疫苗试验结果即将公布之际,莫德纳收复部分失地

10月19日 - ** 莫德纳 MRNA.O 股价上涨5%至229美元,收复了上周五 (link) 下跌7.8%的失地

** 股价较周四创下的52周高点242.29美元仍低约5.5%

** 此次反弹主要受与默克公司 MRK.N 联合开发的晚期 (link) 癌症疫苗数据推动;详细结果将于10月24日在ESMO大会上公布

** 美银全球将目标价从200美元上调至220美元,维持“中性”评级;指出预期中的“积极数据点”已“反映在股价中”

** 医学会议的焦点将集中在治疗效益的程度以及IIB-IV期患者间疗效的一致性上;这将影响投资者对即将公布的肾癌、膀胱癌和肺癌研究结果给予多少肯定

** 计入今日涨幅,MRNA今年以来股价已上涨逾七倍

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10